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Summary 
Noroviruses (NoV) are the most common cause of epidemic gastroenteritis worldwide. The acute 
immune response to NoV in humans is poorly understood, hindering research on prevention and 
treatment. To elucidate the acute immune response and test for cytokine predictors of 
susceptibility to infection, serum samples from two human NoV challenge studies were tested for 
16 cytokines. Subjects who became infected (n=26) were age-matched with subjects who 
remained uninfected following NoV challenge (n=26). Samples were tested from pre-challenge 
and days 1-4 post-challenge. Cytokine responses were compared between infected and 
uninfected groups. Overall, infected individuals exhibited an elevation in Th1 and Th2 cytokines, 
as well as chemokines IL-8 and MCP-1, compared to uninfected individuals (all p<0.05). Most 
cytokines peaked on day 2 post-challenge in infected subjects, and TNF-α, IL-8, and IL-10 
remained elevated through day 3. The only cytokine significantly elevated among infected 
subjects through day 4 post-challenge was IL-10 (p=0.021). Pre-challenge cytokine 
concentrations were not predictive of infection status post-challenge. There were no significant 
changes in serum cytokines among NoV-challenged subjects who remained uninfected. These 
results suggest that NoV infection elicits a Th1 type response with some Th2 activation. 
Persistent elevation of IL-10 among infected subjects is consistent with activation of adaptive 
immune responses, such as B-cell expansion, as well as down-regulation of Th1 cytokines. This 
study presents the first comprehensive description of the acute cytokine response to GI.1 NoV in 
humans. 
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Introduction 
Noroviruses (NoV) comprise seven genogroups in the positive-sense RNA virus family 
Caliciviridae [1, 2]. NoV are responsible for 18% of gastroenteritis worldwide [3]. Despite this 
broad impact, human NoV immunology is poorly understood [4, 5], in part because until 
recently, there was no small animal model or reliable cell culture system for human NoV [6, 7]. 
Furthermore, there are few prospective experimental studies on the acute human innate and 
cellular immune response to NoV.  
The genetic determinants of NoV infection (e.g. secretor blood group antigens) are 
relatively well characterized, but many aspects of protective innate and cellular immunity have 
not been described [8, 9]. Histologic studies [4, 10-12] and in vitro tests of peripheral blood 
mono-nuclear cells [13] suggest cytotoxic and CD8+ T-cell activation with some cells sensitized 
to NoV challenge antigens, but little work has been done in vivo to describe the cytokine 
response to NoV infection. In particular, there is a gap in understanding the acute immune 
response to NoV. Prior studies have shown that adaptive immunity is critical for clearing the 
infection [14], but there is a gap in the knowledge about early pathogenesis of NoV infection. 
Key cytokines for consideration include acute response-related pro-inflammatory cytokines (e.g. 
IL-1, IL-6, and IL-12), chemokines involved in neutrophil and monocyte recruitment (e.g. IL-8 
and MCP-1), and Th1- and Th2-related cytokines (e.g. IFN-γ, IL-2, and TNF-α and IL-4, IL-5, 
and IL-10, respectively) involved in the cellular immune response and initiation of adaptive 
immune mechanisms.  
The goal of this study was two-fold. The first goal was to describe serum cytokine 
responses to NoV infection, including the temporal trends in serum cytokines during the acute 
phase of human NoV infection. The second goal was to use cytokine concentrations pre-
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challenge to predict infection post-challenge. Human serum samples from two prior NoV 
challenge studies that used the same Norwalk virus (GI.1) inoculum were analyzed for a broad 
panel of relevant cytokines [15, 16]. The results have important implications for determining the 
role of specific cytokines in NoV infection. 
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Materials and methods 
Population and samples 
 The samples tested for this study were collected from subjects involved in two separate 
NoV challenge studies, described previously [15, 16]. However, these studies could used the 
same inoculum preparation, were conducted at the same institution, and used very similar 
protocols. Key differences between these two challenge studies (i.e. inoculum dose) were 
accounted for in the modeling strategy of this study. Briefly, the first study enrolled healthy 
secretor-positive adult volunteers, who were challenged with Norwalk virus 8FIIb inoculum at 
Emory University Hospital’s Clinical Interaction Site, part of the Atlanta Clinical and 
Translational Science Institute Clinical Interaction Network, between May 2006 and December 
2006. Volunteers ingested filtered groundwater artificially seeded with 6.5 x 10
7
 genomic 
equivalent copies (GEC) of NoV inoculum, which had been incubated at room temperature in the 
dark for different set lengths of time. Prior to challenge, serum and stool samples were collected. 
During the first 4 days post-challenge, serum samples were collected daily, as were all stool 
samples.  
The second study enrolled healthy secretor-positive adult volunteers, who were also 
challenged with Norwalk virus 8FIIb inoculum at Emory University Hospital’s Clinical 
Interaction Site between February 2008 and September 2009. They were randomized into control 
and intervention groups and administered oysters seeded with 1 x 10
4
 GEC of virus, which had 
been treated with high hydrostatic pressure processing for 5 minutes (intervention) or left 
untreated (control). Pre-challenge stool and serum samples were collected before challenge. 
During the first 4 days post-challenge, serum samples were collected daily, as were all stool 
samples.  
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The Emory University Institutional Review Board approved both studies, and both were 
registered on Clinical Trials.gov (identifiers NCT00313404 and NCT00674336). All subjects 
consented to the future use of all biological specimens from the studies. All specimens were 
stored at -80°C. 
Of the initial participants in both NoV challenge studies, a total of 26 became infected as 
defined by a NoV-positive stool or emesis sample tested by RT-PCR (limit of detection: 3,570 
GEC/g stool) [15, 17]. These 26 were pair-matched by age to 26 of the challenge study 
participants who remained uninfected following NoV challenge. Some infected subjects from 
one challenge group were matched with uninfected subjects from a different challenge group 
because within the same group there were no uninfected individuals within 3 years of age of the 
infected individual. The total sample size for this study was 52 participants (13 from the 2006 
trial, 39 from the 2008-2009 trial). Because the focus of this study is the acute immune response, 
only serum samples from pre-challenge and days 1-4 post-challenge were included, for a total of 
five longitudinal samples per subject. 
Inoculum 
 The two NoV challenge studies included participants who ingested water or shellfish 
seeded with 8FIIb NoV inoculum. The water samples were seeded with identical amounts of 
NoV and stored at room temperature in the dark for varying lengths of time. They showed no 
evidence of titer attenuation over time, as measured by RT-PCR [15]. Therefore, for these 
subjects, the regression models did not control for study arm. The shellfish samples were seeded 
with identical amounts of NoV and treated under varying processing conditions. The inocula 
showed some evidence of attenuation for some treatments.  For subjects from this study, all 
adjusted models controlled for study arm as a surrogate for dose. 
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Detection of viral shedding 
 NoV presence was measured by RT-PCR for all stool and emesis samples at all time 
points during the original challenge studies. A subject with a positive sample at any time point, 
even after day 4 post- exposure, as determined in the original or subsequent studies, was defined 
as infected.  
Detection of cytokines 
 Serum samples from pre-challenge (pre-challenge), and days 1-4 post-challenge (five 
total samples) were analyzed from all study subjects. Serum was collected during the studies, 
processed, and stored at -80°C until testing. Samples were tested by a commercial laboratory 
(EMD Millipore Corporation Discovery and Development Solutions) using a Milliplex human 
cytokine 16-plex assay for IFN-α2, IFN-γ, IL-1a, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12p40, IL-12p70, MCP-1, TNF-α, and TNF-β. Samples were run in duplicate with 
controls. Standard curves were generated using recombinant cytokines and calculated using a 
five parameter logistic model for each cytokine. Lower limits of detection (LLOD) were 3.2 
pg/mL for IFN-γ, IL-10, IL-12p70, IL-1b, IL-2, IL-5, IL-6, IL-8, MCP-1, and TNF-α; 16.0 
pg/mL for TNF-β; and 80.0 pg/mL for IFN-α2, IL-12p40, IL-1ra, IL-1a, and IL-4. Values below 
LLOD were assigned the value of the LLOD. 
Statistical analysis 
 The data were analyzed using SAS 9.4 (Cary, NC, USA). When possible, age and 
inoculum were controlled for in adjusted analyses. Because the exact amount of infectious NoV 
in the inocula for study arms with attenuation was unknown, inoculum was controlled for using a 
categorical variable for each study and study arm. The Wilcoxon signed rank test was to test for 
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the significance of the unadjusted difference between pre-challenge and post-challenge serum 
cytokine levels. Conditional logistic regression was used to evaluate the association between pre-
challenge and post-challenge fold changes in serum cytokine levels (i.e. ratio between post-
challenge and pre-challenge cytokine concentrations), controlling for inoculum and age. To 
summarize the differences between infected and uninfected individuals responses over time 
while accounting for correlation between time points, a mixed linear model was used to test the 
association between log10 cytokine concentration and day post-challenge, stratified by infection 
status with a random effect by subject, autoregressive correlation between different time points 
taken for the same individual, and fixed effect for inoculum. The parameter estimates for the 
effect of each day on log10 cytokine concentration for each stratum were averaged and Student’s 
t-test was used to compare infected and uninfected subjects cytokine responses over time. 
Conditional logistic regression adjusted for inoculum and age was also used to assess whether 
three measures of early cytokine levels or responses could be used as predictors of post-
challenge infection. The measures assessed were pre-challenge log10 cytokine concentration, pre-
challenge to day 1 post-challenge log10 cytokine change, and pre-challenge to day 1 post-
challenge fold change. All cytokines were modeled individually. Differences between groups 
were considered statistically significant at p < 0.05. 
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Results 
 To determine the acute serum cytokine response to GI.1 NoV infection, serum cytokine 
responses in individuals who became infected following experimental challenge were compared 
to those who remained uninfected after challenge, as determined by RT-PCR detection of GI.1 
NoV RNA in stool or emesis samples. Immune responses may differ with age, therefore the 
infected and uninfected subjects were matched for age (Table 1). The study population was 
relatively young, with a mean age of 26.7 years and a median age of 25 years. There was also a 
similar distribution of sex and race between infected and uninfected subjects selected for the 
study, though neither was a matching factor. Some uninfected subjects exhibited symptoms, 
including fever and diarrhea, which is consistent with past NoV challenge studies [16]. All 
infected individuals had higher cumulative shedding than the inoculum dose (data not shown), 
reducing the likelihood of misclassification of infection status because of detection of inoculum 
post-challenge in the absence of infection. Serum samples were available for pre-challenge 
through day 4 post-challenge (five time points) and all samples were tested for 16 serum 
cytokines. Two subjects did not have samples for day 3 and values for these samples were 
imputed using the average of neighboring observations for the same subject. A total of 10 
subjects had invalid test results for one or more cytokine tested (29 total observations). Using 
imputation, all but one of these invalid results was estimated to be below the LLOD.  
 Studies of serum cytokine levels in humans often have high rates of observations below 
the LLOD [18]. Overall of the 16 cytokines tested, nine had greater than 50% of observations 
above the LLOD, and four had greater than 75% of observations above the LLOD (Table 2). In 
general, infected subjects had more samples above the LLOD.  
 To assess whether serum cytokines exhibited a change in concentration following NoV 
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challenge, the Wilcoxon signed rank test was used, stratifying by infection status. Among 
infected individuals, there were significant increases in IL-2, IL-10, MCP-1, and TNF-α in the 
days post-challenge (Figure 1, all p < 0.05). Among uninfected individuals, there were no 
significant changes in serum cytokine concentrations post-challenge compared to pre-challenge. 
Based on conditional logistic regression models controlling for age and inoculum, there were no 
significant differences between infected and uninfected individuals’ changes in serum cytokine 
concentrations between pre-challenge and day 1 post-challenge (data not shown). However, 
infected individuals were significantly more likely to have increased IFN-γ, IL-6, IL-8, IL-
12p70, MCP-1, and TNF-α between pre-challenge and day 2 post-challenge compared to 
uninfected individuals (Table 3). Infected individuals were also significantly more likely to have 
increased levels of TNF-α, IL-8, and IL-10 from pre-challenge to day 3 post-challenge (all 
p<0.05; data not shown). At day 4 post-challenge, the only cytokine significantly elevated over 
pre-challenge levels was IL-10, which was significantly elevated in infected individuals (OR of 
infection based on a two-fold increase in IL-10 from pre-challenge to day 4 post-challenge=3.92, 
p=0.049; data not shown).  
Differences between infected and uninfected individuals over time 
Overall trends in serum cytokine response were analyzed using mixed models to account 
for correlation within subject over time (Figure 2). For infected individuals compared to 
uninfected individuals, there were statistically significant fold changes across the four days post-
challenge from pre-challenge levels in most serum cytokines measured (i.e. IFN-α2, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10, MCP-1, TNF-α, and TNF-β, Figure 2), with all but TNF-β significantly 
higher in infected individuals compared to uninfected individuals. All cytokines peaked at day 2 
post-challenge among infected subjects, with the exception of IL-1ra, but many were elevated by 
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day 1 post-challenge (i.e. IL-2, IL-6, IL-8, MCP-1, and TNF-α) or remained elevated through 
day 4 post-challenge (i.e. IL-10) (Figure 2).  
Pre-challenge predictors of infection  
To determine if pre-challenge serum cytokine concentrations or early cytokine responses 
could predict infection status following challenge, the associations were estimated between 
infection status and three measures of serum cytokines: log10 serum cytokine concentration, log10 
difference between pre-challenge and day 1 post-challenge serum cytokine concentrations, and 
pre-challenge to day 1 post-challenge fold change (i.e. ratio between pre-challenge and day 1 
post-challenge concentrations). Across these measures, the only significant predictor of infection 
status was pre-challenge to day 1 post-challenge log10 change in MCP-1 concentration (data not 
shown). An increase of 1 log10 over this time period was associated with an OR of infection of 
5.74 (p=0.018). No other measures of early cytokine response were statistically significant 
predictors of infection. 
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Discussion 
 This study found overall significant elevation in IFN-a2, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, MCP-1, TNF-α, and TNF-β in infected subjects compared to uninfected subjects. Among 
infected individuals, these cytokines peaked on day 2 post-challenge. The results suggest that 
NoV infection elicits a Th1- and Th2-type response. There also was persistent elevation of IL-10 
among infected subjects, suggestive of an evolving early adaptive immune response and down-
regulation of Th1 cytokines. This study represents the first comprehensive description of the 
dynamics of serum cytokines in the acute time period following NoV challenge, including the 
largest number of cytokines simultaneously described for NoV infection (Table 3).  
 We found that before challenge, individuals who became infected following NoV 
challenge were similar to individuals who did not become infected with regard to all 16 
cytokines tested. From these similar pre-challenge features, differences began to emerge as early 
as 24 hours post-challenge and persisted through day 4 post-challenge. As previously 
documented with human Snow Mountain strain (SMV; GII.2) infection, there was a significant 
Th1 response (i.e. IFN-γ, IL-2, and TNF-α) with significant elevation of one Th2-related 
cytokine (Table 3) [13]. In this study, some Th2 and other cytokines (e.g. IL-4, IL-5, IL-6, IL-8, 
and IL-10) were also significantly elevated following NoV challenge in infected individuals.  
The cytokine responses also resembled results from animal studies (Table 3) but differed 
in the timing and magnitude of cytokine response [19, 20]. These results suggest that the immune 
response by gnotobiotic animals to human NoV may be substantially different from the response 
in humans, perhaps due to the gnotobiotic animals’ immature immune systems [21] or because of 
the use of a different NoV inoculum. 
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Initial response: IL-8, MCP-1 
 We found that IL-8 levels increased in infected subjects by day 1 post-challenge and 
remained elevated through day 3 post-challenge. IL-8 elevation has been identified in prior field 
studies of NoV infection (Table 3) [22, 23]. IL-8 is a powerful chemoattractant for neutrophils 
[24, 25] and intraepithelial lymphocytes [26, 27], and a key mediator of the immune response to 
other gastrointestinal pathogens [28]. Histologic findings from previous human NoV challenge 
studies show increases in granulocyte and monocyte cells in the lamina propria of the small 
intestine 12-48 hours after challenge in infected subjects [29]. Based on the rise in IL-8 alongside 
an increase in MCP-1 and a later rise in IL-6, two monocyte chemoattractants, these observations 
are consistent with neutrophil recruitment acting in concert with monocyte response to NoV 
infection. Earlier work found that GI and GII NoV infection is associated with elevated fecal 
MCP-1, suggesting local monocyte activation [23], but this study is the first to show elevated 
serum MCP-1, suggesting a systemic response as well.   
TNF-α and symptoms 
 In this study, the peak serum TNF-α concentration at 48 hours post-challenge 
corresponded with the time most NoV-infected individuals were symptomatic. TNF-α increases 
cellular permeability, leading to edema mucosal damage [30]. Elevated TNF-α has also been 
associated with NoV infection in past human and animal studies (Table 3) [19, 23]. In some 
gastrointestinal infections, TNF-α is associated with symptoms [31-33]. The association between 
TNF-α and NoV symptoms is an important area for future research. 
IL-6  
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 IL-6 is a multi-functional cytokine with strong pro-inflammatory effects. It is associated 
with damage to the intestinal mucosa [29] and increased frequency of diarrhea [22], suggesting a 
role in pathogenesis and clinical severity of illness. In this study, IL-6 was significantly elevated 
on day 2 post-challenge. This confirms some clinical studies’ identification of the association 
between IL-6 and NoV infection but contrasts with the results from a SMV challenge study 
(Table 3) [13, 22, 23] and suggests possible strain-related differences in immune response. This 
study reported a median maximum serum IL-6 level that was higher than prior studies have 
identified [22, 34], but this discrepancy may be the result of differences in sample collection.  
IL-10 persistently elevated 
 Though IL-10 peaked on day 2 post-challenge, it was significantly elevated through day 4 
post-challenge. This suggests an ongoing role in NoV infection beyond the acute time period. IL-
10 is involved in the Th2 response and B-cell development [35], so its elevation may be 
associated with the development of NoV-specific antibodies, which begin to be detectable 
around or before day 7 post-challenge [36, 37]. Elevated IL-10 in the context of NoV infection 
has been described in prior studies of human NoV (Table 3). IL-10 may also play an anti-
inflammatory role in down-regulating Th1 cytokine production. The significant elevation of IL-
10 in infected subjects following the elevation of Th1 cytokines supports the conclusion that 
NoV elicits a Th1-type response. Furthermore, IL-10-deficient mice exhibit mucosal 
inflammation and epithelial barrier dysfunction following MNV-challenge, whereas wildtype 
mice do not [38]. It is possible that IL-10 plays a similar protective role in NoV-challenged 
humans.  
Strengths and Limitations 
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 This study used rigorously collected human NoV challenge study data, which provided a 
detailed, longitudinal dataset. It is the largest collection of human NoV challenge subjects yet 
studied for serum cytokine response. It represents broadest panel of cytokines yet examined at 
one time for human NoV infection. Some limitations of this study are that it may have been 
underpowered to detect some changes in serum cytokines, the exposure history of subjects prior 
to NoV challenge was unknown, and there is the possibility that the duration of sample storage 
may have caused cytokine degradation [39]. An additional limitation of the study is that though 
RT-PCR is the gold-standard for NoV testing, there may have been individuals who were 
misclassified as uninfected because they shed virus at levels below the limit of detection. 
Conclusion 
 Although NoV remains a major cause of morbidity worldwide, some aspects of the 
immune response continue to be poorly understood. To develop effective vaccines and 
prophylaxis, it is important to understand the human acute immune response to NoV. This study 
demonstrated a Th1- and Th2-type response to GI.1 NoV infection, early elevation of 
chemokines IL-8 and MCP-1, and ongoing elevation of IL-10. This work confirms earlier 
findings of the increase in MCP-1 associated with NoV infection, suggesting macrophage and 
dendritic cell involvement in NoV infection. These findings buttress the existing findings from 
MNV models and enhance the depth of knowledge regarding the human cytokine response to 
NoV. Differences between the results of this study and those of other human and animal work 
may be attributable to strain-related variability in immune response. Future work should consider 
the interplay between the immune response and both clinical outcomes and viral shedding to 
understand NoV pathogenesis and help develop clinical and public health strategies to reduce 
NoV transmission.
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Figure Legends 
 
Figure 1: Comparison of pre-challenge to post-challenge serum cytokine concentrations in 
norovirus-challenged individuals, stratified by infection status (infected n=26, uninfected n=26).  
Values below the lower limit of detection (LLOD) were assigned to the value of the LLOD. 
Significance of change from pre-challenge value was tested using Wilcoxon test and is denoted 
by an asterisk above the relevant category. Interquartile ranges (IQRs) for infected individuals 
(gray boxes) and for uninfected individuals (white boxes) are shown. Dark lines indicate median 
values. Whiskers indicate most extreme value that is no more than 1.5 times the IQR away from 
the bound of the IQR. Circles indicate outliers. *p<0.05, **p<0.01, ***p<0.001 
Figure 2. Mixed linear model results for the association between log10 cytokine change from pre-
challenge to post-challenge by day, with fixed effects for inoculum dose and day and a random 
effect by individual subject. Solid line: infected individuals, dashed line: uninfected individuals. 
Points represent estimates of the effect of day on change in cytokine concentration. Error bars 
indicate one standard error. P-value indicates significance of overall elevation in cytokine 
concentration across days.  
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Figure 1 
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Figure 2 
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Table 1: Characteristics of norovirus-challenged individuals included in analytic sample 
 
 
Total (n=52) Infected (n=26) Uninfected (n=26) 
Age (mean, SD) 26.7 (7.6) 26.7 (7.5) 26.7 (7.9) 
Female  32 (61.5%) 17 (65.4%) 15 (57.7%) 
Race    
     White 25 (48.1%) 15 (57.7%) 10 (38.5%) 
     Black 21 (40.4%) 8 (30.8%) 13 (50.0%) 
     Other 6 (11.5%) 3 (11.5%) 3 (11.5%) 
AGE symptoms
a
  19 (33.9%) 17 (65.4%) 2 (7.7%) 
Modified Vesikari score (mean, SD) 2.6 (2.4) 4.1 (2.4) 1.1 (0.9) 
Abbreviations: SD, standard deviation; AGE, acute gastroenteritis. 
a
AGE symptoms defined as diarrhea (3 or more or >= 400g loose stools in 24 hours) or emesis during days 1-4 post-
challenge.  
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Table 2. Serum cytokine concentrations (pg/mL) of norovirus-challenged individuals pooled 
across days, stratified by infection status
a
. 
All 
 
Infected 
 
Uninfected 
Cytokine Median IQR 
% 
above 
LLOD 
 
Median IQR 
% 
above 
LLOD 
 
Median IQR 
% 
above 
LLOD 
IFN-α2 80.0 80.0-80.0 24.8%  80.0 80.0-133.0 27.9%  80.0 80.0-80.0 21.7% 
IFN-γ 186.5 40.4-
656.1 
90.3%  182.0 67.9-629.3 98.4%  188.3 18.2-669.5 82.2% 
IL-1ra 80.0 80.0-
999.3 
54.3%  80.0 80.0-389.1 73.6%  80.0 80.0-
1,993.9 
34.9% 
IL-1a 163.4 80.0-
433.2 
24.7%  179.8 80.0-433.2 28.5%  80.2 80.0-
433.55 
21.1% 
IL-1b 3.2 3.2-10.3 58.9%  3.3 3.2-18.45 70.2%  3.2 3.2-7.2 48.1% 
IL-2 4.6 3.2-30.1 47.8%  7.5 3.2-38.2 48.0%  3.6 3.2-17.6 47.6% 
IL-4 80.0 80.0-99.9 54.7%  80.0 80.0-170.9 59.4%  80.0 80.0-80.0 50.0% 
IL-5 3.2 3.2-3.9 38.4%  3.2 3.2-6.0 48.1%  3.2 3.2-3.2 28.7% 
IL-6 23.9 3.2-120.2 52.5%  27.8 3.2-93.0 55.5%  21.4 3.2-161.1 49.6% 
IL-8 66.5 20.7-
198.1 
25.4%  81.7 34.2-198.0 28.9%  45.0 11.5-202.4 21.9% 
IL-10 4.4 3.2-29.5 26.8%  17.0 3.2-50.3 33.9%  3.2 3.2-6.2 19.7% 
IL-12p40 80.0 80.0-80.0 70.7%  80.0 80.0-85.0 69.5%  80.0 80.0-80.0 71.9% 
IL-12p70 6.1 3.2-89.8 92.2%  19.5 3.2-86.6 96.9%  3.2 3.2-96.0 87.6% 
MCP-1 612.8 397.1-
832.5 
100.0%  693.5 510.8-
944.3 
100.0%  495.1 329.4-
673.1 
100.0% 
TNF-α 14.3 6.0-27.2 85.3%  15.1 8.3-25.2 87.6%  14.0 4.9-36.2 82.9% 
TNF-β 16.0 16.0-58.5 37.2%  16.0 16.0-100.5 35.7%  16.0 16.0-33.4 38.8% 
Abbreviations: IQR, inter-quartile range; LLOD, lower limit of detection; IFN, interferon; IL, interleukin; MCP, 
monocyte chemoattractant protein; TNF, tumor necrosis factor. 
a
Values below LLOD included in estimates as LLOD value. 
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Table 3. Table comparing results from this study to prior studies of cytokine responses to human 
NoV infection. An ‘x’ indicates significant elevation compared to uninfected controls. Gray cells 
indicate no testing was conducted for that cytokine.  
Study This study
a Lindesmith 
2005 [12] 
Long 2011 [22] 
Chen 2012 
[37] 
Souza 2008 
[18] 
Souza 
2007 [19] 
NoV genogroup GI.1 GII.2 Mixed Mixed GII.4 GII.4 
Subjects Human Human Human Human Gn Calf Gn Pig 
Study design Challenge Challenge 
Observational 
cohort 
Cross-
sectional 
Challenge Challenge 
Cytokine 
IFN-α x 
IFN-α2 ns 
IFN-γ x x ns x
b 
x 
IL-1ra ns 
IL-1a ns 
IL-1b ns 
IL-2 x x 
IL-4 ns ns ns x
b
 x 
IL-5 ns x x 
IL-6 x ns x x 
IL-8 x x x 
IL-10 x ns ns x
b
 x 
IL-12 x
b
 x 
IL-12p40 ns 
IL-12p70 x 
MCP-1 x x 
TNF-α x ns ns x
b
 
TNF-β ns 
Abbreviations: ns, not significant; NoV, norovirus; Gn, gnotobiotic. 
a
Modeled using conditional logistic regression conditional on inoculum dose and adjusted for age. 
b
Cytokine 
concentrations were elevated  
compared to controls but no statistical testing was conducted. 
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Summary 
Noroviruses (NoV) are the most common cause of epidemic gastroenteritis worldwide. The acute 
immune response to NoV in humans is poorly understood, hindering research on prevention and 
treatment. To elucidate the acute immune response and test for cytokine predictors of 
susceptibility to infection, serum samples from two human NoV challenge studies were tested for 
16 cytokines. Subjects who became infected (n=26) were age-matched with subjects who 
remained uninfected following NoV challenge (n=26). Samples were tested from pre-challenge 
and days 1-4 post-challenge. Cytokine responses were compared between infected and 
uninfected groups. Overall, infected individuals exhibited an elevation in Th1 and Th2 cytokines, 
as well as chemokines IL-8 and MCP-1, compared to uninfected individuals (all p<0.05). Most 
cytokines peaked on day 2 post-challenge in infected subjects, and TNF-α, IL-8, and IL-10 
remained elevated through day 3. The only cytokine significantly elevated among infected 
subjects through day 4 post-challenge was IL-10 (p=0.021). Pre-challenge cytokine 
concentrations were not predictive of infection status post-challenge. There were no significant 
changes in serum cytokines among NoV-challenged subjects who remained uninfected. These 
results suggest that NoV infection elicits a Th1 type response with some Th2 activation. 
Persistent elevation of IL-10 among infected subjects is consistent with activation of adaptive 
immune responses, such as B-cell expansion, as well as down-regulation of Th1 cytokines. This 
study presents the first comprehensive description of the acute cytokine response to GI.1 NoV in 
humans. 
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Introduction 
Noroviruses (NoV) comprise seven genogroups in the positive-sense RNA virus family 
Caliciviridae [1, 2]. NoV are responsible for 18% of gastroenteritis worldwide [3]. Despite this 
broad impact, human NoV immunology is poorly understood [4, 5], in part because until 
recently, there was no small animal model or reliable cell culture system for human NoV [6, 7]. 
Furthermore, there are few prospective experimental studies on the acute human innate and 
cellular immune response to NoV.  
The genetic determinants of NoV infection (e.g. secretor blood group antigens) are 
relatively well characterized, but many aspects of protective innate and cellular immunity have 
not been described [8, 9]. Histologic studies [4, 10-12] and in vitro tests of peripheral blood 
mono-nuclear cells [13] suggest cytotoxic and CD8+ T-cell activation with some cells sensitized 
to NoV challenge antigens, but little work has been done in vivo to describe the cytokine 
response to NoV infection. In particular, there is a gap in understanding the acute immune 
response to NoV. Prior studies have shown that adaptive immunity is critical for clearing the 
infection [14], but there is a gap in the knowledge about early pathogenesis of NoV infection. 
Key cytokines for consideration include acute response-related pro-inflammatory cytokines (e.g. 
IL-1, IL-6, and IL-12), chemokines involved in neutrophil and monocyte recruitment (e.g. IL-8 
and MCP-1), and Th1- and Th2-related cytokines (e.g. IFN-γ, IL-2, and TNF-α and IL-4, IL-5, 
and IL-10, respectively) involved in the cellular immune response and initiation of adaptive 
immune mechanisms.  
The goal of this study was two-fold. The first goal was to describe serum cytokine 
responses to NoV infection, including the temporal trends in serum cytokines during the acute 
phase of human NoV infection. The second goal was to use cytokine concentrations pre-
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challenge to predict infection post-challenge. Human serum samples from two prior NoV 
challenge studies that used the same Norwalk virus (GI.1) inoculum were analyzed for a broad 
panel of relevant cytokines [15, 16]. The results have important implications for determining the 
role of specific cytokines in NoV infection. 
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Materials and methods 
Population and samples 
 The samples tested for this study were collected from subjects involved in two separate 
NoV challenge studies, described previously [15, 16]. However, these studies could used the 
same inoculum preparation, were conducted at the same institution, and used very similar 
protocols. Key differences between these two challenge studies (i.e. inoculum dose) were 
accounted for in the modeling strategy of this study. Briefly, the first study enrolled healthy 
secretor-positive adult volunteers, who were challenged with Norwalk virus 8FIIb inoculum at 
Emory University Hospital’s Clinical Interaction Site, part of the Atlanta Clinical and 
Translational Science Institute Clinical Interaction Network, between May 2006 and December 
2006. Volunteers ingested filtered groundwater artificially seeded with 6.5 x 10
7
 genomic 
equivalent copies (GEC) of NoV inoculum, which had been incubated at room temperature in the 
dark for different set lengths of time. Prior to challenge, serum and stool samples were collected. 
During the first 4 days post-challenge, serum samples were collected daily, as were all stool 
samples.  
The second study enrolled healthy secretor-positive adult volunteers, who were also 
challenged with Norwalk virus 8FIIb inoculum at Emory University Hospital’s Clinical 
Interaction Site between February 2008 and September 2009. They were randomized into control 
and intervention groups and administered oysters seeded with 1 x 10
4
 GEC of virus, which had 
been treated with high hydrostatic pressure processing for 5 minutes (intervention) or left 
untreated (control). Pre-challenge stool and serum samples were collected before challenge. 
During the first 4 days post-challenge, serum samples were collected daily, as were all stool 
samples.  
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The Emory University Institutional Review Board approved both studies, and both were 
registered on Clinical Trials.gov (identifiers NCT00313404 and NCT00674336). All subjects 
consented to the future use of all biological specimens from the studies. All specimens were 
stored at -80°C. 
Of the initial participants in both NoV challenge studies, a total of 26 became infected as 
defined by a NoV-positive stool or emesis sample tested by RT-PCR (limit of detection: 3,570 
GEC/g stool) [15, 17]. These 26 were pair-matched by age to 26 of the challenge study 
participants who remained uninfected following NoV challenge. Some infected subjects from 
one challenge group were matched with uninfected subjects from a different challenge group 
because within the same group there were no uninfected individuals within 3 years of age of the 
infected individual. The total sample size for this study was 52 participants (13 from the 2006 
trial, 39 from the 2008-2009 trial). Because the focus of this study is the acute immune response, 
only serum samples from pre-challenge and days 1-4 post-challenge were included, for a total of 
five longitudinal samples per subject. 
Inoculum 
 The two NoV challenge studies included participants who ingested water or shellfish 
seeded with 8FIIb NoV inoculum. The water samples were seeded with identical amounts of 
NoV and stored at room temperature in the dark for varying lengths of time. They showed no 
evidence of titer attenuation over time, as measured by RT-PCR [15]. Therefore, for these 
subjects, the regression models did not control for study arm. The shellfish samples were seeded 
with identical amounts of NoV and treated under varying processing conditions. The inocula 
showed some evidence of attenuation for some treatments.  For subjects from this study, all 
adjusted models controlled for study arm as a surrogate for dose. 
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Detection of viral shedding 
 NoV presence was measured by RT-PCR for all stool and emesis samples at all time 
points during the original challenge studies. A subject with a positive sample at any time point, 
even after day 4 post- exposure, as determined in the original or subsequent studies, was defined 
as infected.  
Detection of cytokines 
 Serum samples from pre-challenge (pre-challenge), and days 1-4 post-challenge (five 
total samples) were analyzed from all study subjects. Serum was collected during the studies, 
processed, and stored at -80°C until testing. Samples were tested by a commercial laboratory 
(EMD Millipore Corporation Discovery and Development Solutions) using a Milliplex human 
cytokine 16-plex assay for IFN-α2, IFN-γ, IL-1a, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12p40, IL-12p70, MCP-1, TNF-α, and TNF-β. Samples were run in duplicate with 
controls. Standard curves were generated using recombinant cytokines and calculated using a 
five parameter logistic model for each cytokine. Lower limits of detection (LLOD) were 3.2 
pg/mL for IFN-γ, IL-10, IL-12p70, IL-1b, IL-2, IL-5, IL-6, IL-8, MCP-1, and TNF-α; 16.0 
pg/mL for TNF-β; and 80.0 pg/mL for IFN-α2, IL-12p40, IL-1ra, IL-1a, and IL-4. Values below 
LLOD were assigned the value of the LLOD. 
Statistical analysis 
 The data were analyzed using SAS 9.4 (Cary, NC, USA). When possible, age and 
inoculum were controlled for in adjusted analyses. Because the exact amount of infectious NoV 
in the inocula for study arms with attenuation was unknown, inoculum was controlled for using a 
categorical variable for each study and study arm. The Wilcoxon signed rank test was to test for 
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the significance of the unadjusted difference between pre-challenge and post-challenge serum 
cytokine levels. Conditional logistic regression was used to evaluate the association between pre-
challenge and post-challenge fold changes in serum cytokine levels (i.e. ratio between post-
challenge and pre-challenge cytokine concentrations), controlling for inoculum and age. To 
summarize the differences between infected and uninfected individuals responses over time 
while accounting for correlation between time points, a mixed linear model was used to test the 
association between log10 cytokine concentration and day post-challenge, stratified by infection 
status with a random effect by subject, autoregressive correlation between different time points 
taken for the same individual, and fixed effect for inoculum. The parameter estimates for the 
effect of each day on log10 cytokine concentration for each stratum were averaged and Student’s 
t-test was used to compare infected and uninfected subjects cytokine responses over time. 
Conditional logistic regression adjusted for inoculum and age was also used to assess whether 
three measures of early cytokine levels or responses could be used as predictors of post-
challenge infection. The measures assessed were pre-challenge log10 cytokine concentration, pre-
challenge to day 1 post-challenge log10 cytokine change, and pre-challenge to day 1 post-
challenge fold change. All cytokines were modeled individually. Differences between groups 
were considered statistically significant at p < 0.05. 
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Results 
 To determine the acute serum cytokine response to GI.1 NoV infection, serum cytokine 
responses in individuals who became infected following experimental challenge were compared 
to those who remained uninfected after challenge, as determined by RT-PCR detection of GI.1 
NoV RNA in stool or emesis samples. Immune responses may differ with age, therefore the 
infected and uninfected subjects were matched for age (Table 1). The study population was 
relatively young, with a mean age of 26.7 years and a median age of 25 years. There was also a 
similar distribution of sex and race between infected and uninfected subjects selected for the 
study, though neither was a matching factor. Some uninfected subjects exhibited symptoms, 
including fever and diarrhea, which is consistent with past NoV challenge studies [16]. All 
infected individuals had higher cumulative shedding than the inoculum dose (data not shown), 
reducing the likelihood of misclassification of infection status because of detection of inoculum 
post-challenge in the absence of infection. Serum samples were available for pre-challenge 
through day 4 post-challenge (five time points) and all samples were tested for 16 serum 
cytokines. Two subjects did not have samples for day 3 and values for these samples were 
imputed using the average of neighboring observations for the same subject. A total of 10 
subjects had invalid test results for one or more cytokine tested (29 total observations). Using 
imputation, all but one of these invalid results was estimated to be below the LLOD.  
 Studies of serum cytokine levels in humans often have high rates of observations below 
the LLOD [18]. Overall of the 16 cytokines tested, nine had greater than 50% of observations 
above the LLOD, and four had greater than 75% of observations above the LLOD (Table 2). In 
general, infected subjects had more samples above the LLOD.  
 To assess whether serum cytokines exhibited a change in concentration following NoV 
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challenge, the Wilcoxon signed rank test was used, stratifying by infection status. Among 
infected individuals, there were significant increases in IL-2, IL-10, MCP-1, and TNF-α in the 
days post-challenge (Figure 1, all p < 0.05). Among uninfected individuals, there were no 
significant changes in serum cytokine concentrations post-challenge compared to pre-challenge. 
Based on conditional logistic regression models controlling for age and inoculum, there were no 
significant differences between infected and uninfected individuals’ changes in serum cytokine 
concentrations between pre-challenge and day 1 post-challenge (data not shown). However, 
infected individuals were significantly more likely to have increased IFN-γ, IL-6, IL-8, IL-
12p70, MCP-1, and TNF-α between pre-challenge and day 2 post-challenge compared to 
uninfected individuals (Table 3). Infected individuals were also significantly more likely to have 
increased levels of TNF-α, IL-8, and IL-10 from pre-challenge to day 3 post-challenge (all 
p<0.05; data not shown). At day 4 post-challenge, the only cytokine significantly elevated over 
pre-challenge levels was IL-10, which was significantly elevated in infected individuals (OR of 
infection based on a two-fold increase in IL-10 from pre-challenge to day 4 post-challenge=3.92, 
p=0.049; data not shown).  
Differences between infected and uninfected individuals over time 
Overall trends in serum cytokine response were analyzed using mixed models to account 
for correlation within subject over time (Figure 2). For infected individuals compared to 
uninfected individuals, there were statistically significant fold changes across the four days post-
challenge from pre-challenge levels in most serum cytokines measured (i.e. IFN-α2, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10, MCP-1, TNF-α, and TNF-β, Figure 2), with all but TNF-β significantly 
higher in infected individuals compared to uninfected individuals. All cytokines peaked at day 2 
post-challenge among infected subjects, with the exception of IL-1ra, but many were elevated by 
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day 1 post-challenge (i.e. IL-2, IL-6, IL-8, MCP-1, and TNF-α) or remained elevated through 
day 4 post-challenge (i.e. IL-10) (Figure 2).  
Pre-challenge predictors of infection  
To determine if pre-challenge serum cytokine concentrations or early cytokine responses 
could predict infection status following challenge, the associations were estimated between 
infection status and three measures of serum cytokines: log10 serum cytokine concentration, log10 
difference between pre-challenge and day 1 post-challenge serum cytokine concentrations, and 
pre-challenge to day 1 post-challenge fold change (i.e. ratio between pre-challenge and day 1 
post-challenge concentrations). Across these measures, the only significant predictor of infection 
status was pre-challenge to day 1 post-challenge log10 change in MCP-1 concentration (data not 
shown). An increase of 1 log10 over this time period was associated with an OR of infection of 
5.74 (p=0.018). No other measures of early cytokine response were statistically significant 
predictors of infection. 
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Discussion 
 This study found overall significant elevation in IFN-a2, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, MCP-1, TNF-α, and TNF-β in infected subjects compared to uninfected subjects. Among 
infected individuals, these cytokines peaked on day 2 post-challenge. The results suggest that 
NoV infection elicits a Th1- and Th2-type response. There also was persistent elevation of IL-10 
among infected subjects, suggestive of an evolving early adaptive immune response and down-
regulation of Th1 cytokines. This study represents the first comprehensive description of the 
dynamics of serum cytokines in the acute time period following NoV challenge, including the 
largest number of cytokines simultaneously described for NoV infection (Table 3).  
 We found that before challenge, individuals who became infected following NoV 
challenge were similar to individuals who did not become infected with regard to all 16 
cytokines tested. From these similar pre-challenge features, differences began to emerge as early 
as 24 hours post-challenge and persisted through day 4 post-challenge. As previously 
documented with human Snow Mountain strain (SMV; GII.2) infection, there was a significant 
Th1 response (i.e. IFN-γ, IL-2, and TNF-α) with significant elevation of one Th2-related 
cytokine (Table 3) [13]. In this study, some Th2 and other cytokines (e.g. IL-4, IL-5, IL-6, IL-8, 
and IL-10) were also significantly elevated following NoV challenge in infected individuals.  
The cytokine responses also resembled results from animal studies (Table 3) but differed 
in the timing and magnitude of cytokine response [19, 20]. These results suggest that the immune 
response by gnotobiotic animals to human NoV may be substantially different from the response 
in humans, perhaps due to the gnotobiotic animals’ immature immune systems [21] or because of 
the use of a different NoV inoculum. 
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Initial response: IL-8, MCP-1 
 We found that IL-8 levels increased in infected subjects by day 1 post-challenge and 
remained elevated through day 3 post-challenge. IL-8 elevation has been identified in prior field 
studies of NoV infection (Table 3) [22, 23]. IL-8 is a powerful chemoattractant for neutrophils 
[24, 25] and intraepithelial lymphocytes [26, 27], and a key mediator of the immune response to 
other gastrointestinal pathogens [28]. Histologic findings from previous human NoV challenge 
studies show increases in granulocyte and monocyte cells in the lamina propria of the small 
intestine 12-48 hours after challenge in infected subjects [29]. Based on the rise in IL-8 alongside 
an increase in MCP-1 and a later rise in IL-6, two monocyte chemoattractants, these observations 
are consistent with neutrophil recruitment acting in concert with monocyte response to NoV 
infection. Earlier work found that GI and GII NoV infection is associated with elevated fecal 
MCP-1, suggesting local monocyte activation [23], but this study is the first to show elevated 
serum MCP-1, suggesting a systemic response as well.   
TNF-α and symptoms 
 In this study, the peak serum TNF-α concentration at 48 hours post-challenge 
corresponded with the time most NoV-infected individuals were symptomatic. TNF-α increases 
cellular permeability, leading to edema mucosal damage [30]. Elevated TNF-α has also been 
associated with NoV infection in past human and animal studies (Table 3) [19, 23]. In some 
gastrointestinal infections, TNF-α is associated with symptoms [31-33]. The association between 
TNF-α and NoV symptoms is an important area for future research. 
IL-6  
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 IL-6 is a multi-functional cytokine with strong pro-inflammatory effects. It is associated 
with damage to the intestinal mucosa [29] and increased frequency of diarrhea [22], suggesting a 
role in pathogenesis and clinical severity of illness. In this study, IL-6 was significantly elevated 
on day 2 post-challenge. This confirms some clinical studies’ identification of the association 
between IL-6 and NoV infection but contrasts with the results from a SMV challenge study 
(Table 3) [13, 22, 23] and suggests possible strain-related differences in immune response. This 
study reported a median maximum serum IL-6 level that was higher than prior studies have 
identified [22, 34], but this discrepancy may be the result of differences in sample collection.  
IL-10 persistently elevated 
 Though IL-10 peaked on day 2 post-challenge, it was significantly elevated through day 4 
post-challenge. This suggests an ongoing role in NoV infection beyond the acute time period. IL-
10 is involved in the Th2 response and B-cell development [35], so its elevation may be 
associated with the development of NoV-specific antibodies, which begin to be detectable 
around or before day 7 post-challenge [36, 37]. Elevated IL-10 in the context of NoV infection 
has been described in prior studies of human NoV (Table 3). IL-10 may also play an anti-
inflammatory role in down-regulating Th1 cytokine production. The significant elevation of IL-
10 in infected subjects following the elevation of Th1 cytokines supports the conclusion that 
NoV elicits a Th1-type response. Furthermore, IL-10-deficient mice exhibit mucosal 
inflammation and epithelial barrier dysfunction following MNV-challenge, whereas wildtype 
mice do not [38]. It is possible that IL-10 plays a similar protective role in NoV-challenged 
humans.  
Strengths and Limitations 
Page 39 of 75 Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
15 
 
 This study used rigorously collected human NoV challenge study data, which provided a 
detailed, longitudinal dataset. It is the largest collection of human NoV challenge subjects yet 
studied for serum cytokine response. It represents broadest panel of cytokines yet examined at 
one time for human NoV infection. Some limitations of this study are that it may have been 
underpowered to detect some changes in serum cytokines, the exposure history of subjects prior 
to NoV challenge was unknown, and there is the possibility that the duration of sample storage 
may have caused cytokine degradation [39]. An additional limitation of the study is that though 
RT-PCR is the gold-standard for NoV testing, there may have been individuals who were 
misclassified as uninfected because they shed virus at levels below the limit of detection. 
Conclusion 
 Although NoV remains a major cause of morbidity worldwide, some aspects of the 
immune response continue to be poorly understood. To develop effective vaccines and 
prophylaxis, it is important to understand the human acute immune response to NoV. This study 
demonstrated a Th1- and Th2-type response to GI.1 NoV infection, early elevation of 
chemokines IL-8 and MCP-1, and ongoing elevation of IL-10. This work confirms earlier 
findings of the increase in MCP-1 associated with NoV infection, suggesting macrophage and 
dendritic cell involvement in NoV infection. These findings buttress the existing findings from 
MNV models and enhance the depth of knowledge regarding the human cytokine response to 
NoV. Differences between the results of this study and those of other human and animal work 
may be attributable to strain-related variability in immune response. Future work should consider 
the interplay between the immune response and both clinical outcomes and viral shedding to 
understand NoV pathogenesis and help develop clinical and public health strategies to reduce 
NoV transmission.
Page 40 of 75Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
16 
 
Acknowledgements  
 This work was supported by the F30 grant (K.L.N., grant 1F30DK100097-01), the ARCS 
Foundation (K.L.N), the National Institute of Allergy and Infectious Diseases at the National 
Institutes of Health (J.S.L., grant 1K01AI087724-01), and the Emory University Global Health 
Institute (J.S.L.). The contents of this paper are solely the responsibility of the authors and do not 
necessarily represent the official views of the National Institutes of Health. 
Page 41 of 75 Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
17 
 
References 
1. Vinje J. Advances in Laboratory Methods for Detection and Typing of Norovirus. Journal of 
clinical microbiology 2015; 53:373-81. 
2. Green KY. Caliciviridae: The Noroviruses. In: Knipe DMH, P., ed. Fields Virology: L.W.W., 2013. 
3. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman 
BA. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-
analysis. The Lancet infectious diseases 2014; 14:725-30. 
4. Leon JS SM, Qiuhong W, Smith ER, Saif LJ and Moe CL. Immunology of Norovirus Infection. In: M 
V, ed. Immunity Against Mucosal Pathogens. New York: Springer, 2008:219-62. 
5. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, Weber DJ, Baric RS. 
Heterotypic humoral and cellular immune responses following Norwalk virus infection. Journal 
of virology 2010; 84:1800-15. 
6. Taube S, Kolawole AO, Hohne M, Wilkinson JE, Handley SA, Perry JW, Thackray LB, Akkina R, 
Wobus CE. A mouse model for human norovirus. mBio 2013; 4. 
7. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, Gonzalez-Hernandez MB, Iovine 
NM, Wobus CE, Vinje J, Tibbetts SA, Wallet SM, Karst SM. Enteric bacteria promote human and 
mouse norovirus infection of B cells. Science 2014; 346:755-9. 
8. Tan M, Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS 
pathogens 2010; 6:e1000983. 
9. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with 
secretor status genotyped from sera. Journal of medical virology 2005; 77:116-20. 
10. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute 
gastroenteritis caused by Norwalk agent. The New England journal of medicine 1977; 297:86-9. 
11. Schreiber DS, Blacklow NR, Trier JS. The small intestinal lesion induced by Hawaii agent acute 
infectious nonbacterial gastroenteritis. The Journal of infectious diseases 1974; 129:705-8. 
12. Troeger H, Loddenkemper C, Schneider T, Schreier E, Epple HJ, Zeitz M, Fromm M, Schulzke JD. 
Structural and functional changes of the duodenum in human norovirus infection. Gut 2009; 
58:1070-7. 
13. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity 
following Snow Mountain virus challenge. Journal of virology 2005; 79:2900-9. 
14. Chachu KA, Strong DW, LoBue AD, Wobus CE, Baric RS, Virgin HWt. Antibody is critical for the 
clearance of murine norovirus infection. Journal of virology 2008; 82:6610-7. 
15. Seitz SR, Leon JS, Schwab KJ, Lyon GM, Dowd M, McDaniels M, Abdulhafid G, Fernandez ML, 
Lindesmith LC, Baric RS, Moe CL. Norovirus infectivity in humans and persistence in water. 
Applied and environmental microbiology 2011; 77:6884-8. 
16. Leon JS, Kingsley DH, Montes JS, Richards GP, Lyon GM, Abdulhafid GM, Seitz SR, Fernandez ML, 
Teunis PF, Flick GJ, Moe CL. Randomized, double-blinded clinical trial for human norovirus 
inactivation in oysters by high hydrostatic pressure processing. Applied and environmental 
microbiology 2011; 77:5476-82. 
17. Kirby AE, Shi J, Montes J, Lichtenstein M, Moe CL. Disease course and viral shedding in 
experimental Norwalk virus and Snow Mountain virus infection. Journal of medical virology 
2014. 
18. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of 
multiplex cytokine levels in asymptomatic persons. Cancer epidemiology, biomarkers & 
prevention : a publication of the American Association for Cancer Research, cosponsored by the 
American Society of Preventive Oncology 2008; 17:3450-6. 
Page 42 of 75Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
18 
9. Souza M, Azevedo MS, Jung K, Cheetham S, Saif LJ. Pathogenesis and immune responses in 
gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. 
Journal of virology 2008; 82:1777-86. 
0. Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ. Cytokine and antibody responses in 
gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). Journal of 
virology 2007; 81:9183-92. 
1. Wagner RD. Effects of microbiota on GI health: gnotobiotic research. Advances in experimental 
medicine and biology 2008; 635:41-56. 
2. Chen SM, Lin CP, Tsai JD, Chao YH, Sheu JN. The significance of serum and fecal levels of 
interleukin-6 and interleukin-8 in hospitalized children with acute rotavirus and norovirus 
gastroenteritis. Pediatrics and neonatology 2014; 55:120-6. 
3. Long KZ, Garcia C, Ko G, Santos JI, Al Mamun A, Rosado JL, DuPont HL, Nathakumar N. Vitamin A 
modifies the intestinal chemokine and cytokine responses to norovirus infection in Mexican 
children. The Journal of nutrition 2011; 141:957-63. 
4. Kucharzik T, Hudson JT, 3rd, Lugering A, Abbas JA, Bettini M, Lake JG, Evans ME, Ziegler TR, 
Merlin D, Madara JL, Williams IR. Acute induction of human IL-8 production by intestinal 
epithelium triggers neutrophil infiltration without mucosal injury. Gut 2005; 54:1565-72. 
5. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS letters 
1992; 307:97-101. 
6. Roberts AI, Bilenker M, Ebert EC. Intestinal intraepithelial lymphocytes have a promiscuous 
interleukin-8 receptor. Gut 1997; 40:333-8. 
7. Ebert EC. Human intestinal intraepithelial lymphocytes have potent chemotactic activity. 
Gastroenterology 1995; 109:1154-9. 
8. Casola A, Estes MK, Crawford SE, Ogra PL, Ernst PB, Garofalo RP, Crowe SE. Rotavirus infection of 
cultured intestinal epithelial cells induces secretion of CXC and CC chemokines. 
Gastroenterology 1998; 114:947-55. 
9. Schreiber DS, Blacklow NR, Trier JS. The mucosal lesion of the proximal small intestine in acute 
infectious nonbacterial gastroenteritis. The New England journal of medicine 1973; 288:1318-
23. 
0. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. 
Mucosal immunology 2014; 7:6-19. 
1. Peterson KM, Shu J, Duggal P, Haque R, Mondal D, Petri WA, Jr. Association between TNF-alpha 
and Entamoeba histolytica diarrhea. The American journal of tropical medicine and hygiene 
2010; 82:620-5. 
2. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of 
children with inflammatory bowel disease or infective diarrhoea. Journal of clinical pathology 
1993; 46:757-60. 
3. Greenberg DE, Jiang ZD, Steffen R, Verenker MP, DuPont HL. Markers of inflammation in 
bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli 
pathogenicity. The Journal of infectious diseases 2002; 185:944-9. 
4. Chen SM, Ku MS, Lee MY, Tsai JD, Sheu JN. Diagnostic performance of serum interleukin-6 and 
interleukin-10 levels and clinical predictors in children with rotavirus and norovirus 
gastroenteritis. Cytokine 2012; 59:299-304. 
5. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. 
Cytokine & growth factor reviews 2010; 21:331-44. 
6. Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, Atmar RL. Mucosal and 
Cellular Immune Responses to Norwalk Virus. The Journal of infectious diseases 2015. 
Page 43 of 75 Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
19 
7. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular 
immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 
108:241-7. 
8. Basic M, Keubler LM, Buettner M, Achard M, Breves G, Schroder B, Smoczek A, Jorns A, 
Wedekind D, Zschemisch NH, Gunther C, Neumann D, Lienenklaus S, Weiss S, Hornef MW, 
Mahler M, Bleich A. Norovirus triggered microbiota-driven mucosal inflammation in interleukin 
10-deficient mice. Inflammatory bowel diseases 2014; 20:431-43. 
9. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine 
measurements in clinical trials with multiplex immunoassays. BMC immunology 2009; 10:52. 
Page 44 of 75Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
20 
 
Figure Legends 
 
Figure 1: Comparison of pre-challenge to post-challenge serum cytokine concentrations in 
norovirus-challenged individuals, stratified by infection status (infected n=26, uninfected n=26).  
Values below the lower limit of detection (LLOD) were assigned to the value of the LLOD. 
Significance of change from pre-challenge value was tested using Wilcoxon test and is denoted 
by an asterisk above the relevant category. Interquartile ranges (IQRs) for infected individuals 
(gray boxes) and for uninfected individuals (white boxes) are shown. Dark lines indicate median 
values. Whiskers indicate most extreme value that is no more than 1.5 times the IQR away from 
the bound of the IQR. Circles indicate outliers. *p<0.05, **p<0.01, ***p<0.001 
Figure 2. Mixed linear model results for the association between log10 cytokine change from pre-
challenge to post-challenge by day, with fixed effects for inoculum dose and day and a random 
effect by individual subject. Solid line: infected individuals, dashed line: uninfected individuals. 
Points represent estimates of the effect of day on change in cytokine concentration. Error bars 
indicate one standard error. P-value indicates significance of overall elevation in cytokine 
concentration across days.  
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Figure 1 
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Figure 2 
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Table 1: Characteristics of norovirus-challenged individuals included in analytic sample 
 
 
Total (n=52) Infected (n=26) Uninfected (n=26) 
Age (mean, SD) 26.7 (7.6) 26.7 (7.5) 26.7 (7.9) 
Female  32 (61.5%) 17 (65.4%) 15 (57.7%) 
Race    
     White 25 (48.1%) 15 (57.7%) 10 (38.5%) 
     Black 21 (40.4%) 8 (30.8%) 13 (50.0%) 
     Other 6 (11.5%) 3 (11.5%) 3 (11.5%) 
AGE symptoms
a
  19 (33.9%) 17 (65.4%) 2 (7.7%) 
Modified Vesikari score (mean, SD) 2.6 (2.4) 4.1 (2.4) 1.1 (0.9) 
Abbreviations: SD, standard deviation; AGE, acute gastroenteritis. 
a
AGE symptoms defined as diarrhea (3 or more or >= 400g loose stools in 24 hours) or emesis during days 1-4 post-
challenge.  
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Table 2. Serum cytokine concentrations (pg/mL) of norovirus-challenged individuals pooled 
across days, stratified by infection status
a
. 
All 
 
Infected 
 
Uninfected 
Cytokine Median IQR 
% 
above 
LLOD 
 
Median IQR 
% 
above 
LLOD 
 
Median IQR 
% 
above 
LLOD 
IFN-α2 80.0 80.0-80.0 24.8%  80.0 80.0-133.0 27.9%  80.0 80.0-80.0 21.7% 
IFN-γ 186.5 40.4-
656.1 
90.3%  182.0 67.9-629.3 98.4%  188.3 18.2-669.5 82.2% 
IL-1ra 80.0 80.0-
999.3 
54.3%  80.0 80.0-389.1 73.6%  80.0 80.0-
1,993.9 
34.9% 
IL-1a 163.4 80.0-
433.2 
24.7%  179.8 80.0-433.2 28.5%  80.2 80.0-
433.55 
21.1% 
IL-1b 3.2 3.2-10.3 58.9%  3.3 3.2-18.45 70.2%  3.2 3.2-7.2 48.1% 
IL-2 4.6 3.2-30.1 47.8%  7.5 3.2-38.2 48.0%  3.6 3.2-17.6 47.6% 
IL-4 80.0 80.0-99.9 54.7%  80.0 80.0-170.9 59.4%  80.0 80.0-80.0 50.0% 
IL-5 3.2 3.2-3.9 38.4%  3.2 3.2-6.0 48.1%  3.2 3.2-3.2 28.7% 
IL-6 23.9 3.2-120.2 52.5%  27.8 3.2-93.0 55.5%  21.4 3.2-161.1 49.6% 
IL-8 66.5 20.7-
198.1 
25.4%  81.7 34.2-198.0 28.9%  45.0 11.5-202.4 21.9% 
IL-10 4.4 3.2-29.5 26.8%  17.0 3.2-50.3 33.9%  3.2 3.2-6.2 19.7% 
IL-12p40 80.0 80.0-80.0 70.7%  80.0 80.0-85.0 69.5%  80.0 80.0-80.0 71.9% 
IL-12p70 6.1 3.2-89.8 92.2%  19.5 3.2-86.6 96.9%  3.2 3.2-96.0 87.6% 
MCP-1 612.8 397.1-
832.5 
100.0%  693.5 510.8-
944.3 
100.0%  495.1 329.4-
673.1 
100.0% 
TNF-α 14.3 6.0-27.2 85.3%  15.1 8.3-25.2 87.6%  14.0 4.9-36.2 82.9% 
TNF-β 16.0 16.0-58.5 37.2%  16.0 16.0-100.5 35.7%  16.0 16.0-33.4 38.8% 
Abbreviations: IQR, inter-quartile range; LLOD, lower limit of detection; IFN, interferon; IL, interleukin; MCP, 
monocyte chemoattractant protein; TNF, tumor necrosis factor. 
a
Values below LLOD included in estimates as LLOD value. 
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Table 3. Table comparing results from this study to prior studies of cytokine responses to human 
NoV infection. An ‘x’ indicates significant elevation compared to uninfected controls. Gray cells 
indicate no testing was conducted for that cytokine.  
Study This study
a Lindesmith 
2005 [12] 
Long 2011 [22] 
Chen 2012 
[37] 
Souza 2008 
[18] 
Souza 
2007 [19] 
NoV genogroup GI.1 GII.2 Mixed Mixed GII.4 GII.4 
Subjects Human Human Human Human Gn Calf Gn Pig 
Study design Challenge Challenge 
Observational 
cohort 
Cross-
sectional 
Challenge Challenge 
Cytokine 
IFN-α x 
IFN-α2 ns 
IFN-γ x x ns x
b 
x 
IL-1ra ns 
IL-1a ns 
IL-1b ns 
IL-2 x x 
IL-4 ns ns ns x
b
 x 
IL-5 ns x x 
IL-6 x ns x x 
IL-8 x x x 
IL-10 x ns ns x
b
 x 
IL-12 x
b
 x 
IL-12p40 ns 
IL-12p70 x 
MCP-1 x x 
TNF-α x ns ns x
b
 
TNF-β ns 
Abbreviations: ns, not significant; NoV, norovirus; Gn, gnotobiotic. 
a
Modeled using conditional logistic regression conditional on inoculum dose and adjusted for age. 
b
Cytokine 
concentrations were elevated  
compared to controls but no statistical testing was conducted. 
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Summary 
Noroviruses (NoV) are the most common cause of epidemic gastroenteritis worldwide. The acute 
immune response to NoV in humans is poorly understood, hindering research on prevention and 
treatment. To elucidate the acute immune response and test for cytokine predictors of 
susceptibility to infection, serum samples from two human NoV challenge studies were tested for 
16 cytokines. Subjects who became infected (n=26) were age-matched with subjects who 
remained uninfected following NoV challenge (n=26). Samples were tested from pre-challenge 
and days 1-4 post-challenge. Cytokine responses were compared between infected and 
uninfected groups. Overall, infected individuals exhibited an elevation in Th1 and Th2 cytokines, 
as well as chemokines IL-8 and MCP-1, compared to uninfected individuals (all p<0.05). Most 
cytokines peaked on day 2 post-challenge in infected subjects, and TNF-α, IL-8, and IL-10 
remained elevated through day 3. The only cytokine significantly elevated among infected 
subjects through day 4 post-challenge was IL-10 (p=0.021). Pre-challenge cytokine 
concentrations were not predictive of infection status post-challenge. There were no significant 
changes in serum cytokines among NoV-challenged subjects who remained uninfected. These 
results suggest that NoV infection elicits a Th1 type response with some Th2 activation. 
Persistent elevation of IL-10 among infected subjects is consistent with activation of adaptive 
immune responses, such as B-cell expansion, as well as down-regulation of Th1 cytokines. This 
study presents the first comprehensive description of the acute cytokine response to GI.1 NoV in 
humans. 
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Introduction 
Noroviruses (NoV) comprise seven genogroups in the positive-sense RNA virus family 
Caliciviridae [1, 2]. NoV are responsible for 18% of gastroenteritis worldwide [3]. Despite this 
broad impact, human NoV immunology is poorly understood [4, 5], in part because until 
recently, there was no small animal model or reliable cell culture system for human NoV [6, 7]. 
Furthermore, there are few prospective experimental studies on the acute human innate and 
cellular immune response to NoV.  
The genetic determinants of NoV infection (e.g. secretor blood group antigens) are 
relatively well characterized, but many aspects of protective innate and cellular immunity have 
not been described [8, 9]. Histologic studies [4, 10-12] and in vitro tests of peripheral blood 
mono-nuclear cells [13] suggest cytotoxic and CD8+ T-cell activation with some cells sensitized 
to NoV challenge antigens, but little work has been done in vivo to describe the cytokine 
response to NoV infection. In particular, there is a gap in understanding the acute immune 
response to NoV. Prior studies have shown that adaptive immunity is critical for clearing the 
infection [14], but there is a gap in the knowledge about early pathogenesis of NoV infection. 
Key cytokines for consideration include acute response-related pro-inflammatory cytokines (e.g. 
IL-1, IL-6, and IL-12), chemokines involved in neutrophil and monocyte recruitment (e.g. IL-8 
and MCP-1), and Th1- and Th2-related cytokines (e.g. IFN-γ, IL-2, and TNF-α and IL-4, IL-5, 
and IL-10, respectively) involved in the cellular immune response and initiation of adaptive 
immune mechanisms.  
The goal of this study was two-fold. The first goal was to describe serum cytokine 
responses to NoV infection, including the temporal trends in serum cytokines during the acute 
phase of human NoV infection. The second goal was to use cytokine concentrations pre-
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challenge to predict infection post-challenge. Human serum samples from two prior NoV 
challenge studies that used the same Norwalk virus (GI.1) inoculum were analyzed for a broad 
panel of relevant cytokines [15, 16]. The results have important implications for determining the 
role of specific cytokines in NoV infection. 
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Materials and methods 
Population and samples 
 The samples tested for this study were collected from subjects involved in two separate 
NoV challenge studies, described previously [15, 16]. However, these studies could used the 
same inoculum preparation, were conducted at the same institution, and used very similar 
protocols. Key differences between these two challenge studies (i.e. inoculum dose) were 
accounted for in the modeling strategy of this study. Briefly, the first study enrolled healthy 
secretor-positive adult volunteers, who were challenged with Norwalk virus 8FIIb inoculum at 
Emory University Hospital’s Clinical Interaction Site, part of the Atlanta Clinical and 
Translational Science Institute Clinical Interaction Network, between May 2006 and December 
2006. Volunteers ingested filtered groundwater artificially seeded with 6.5 x 10
7
 genomic 
equivalent copies (GEC) of NoV inoculum, which had been incubated at room temperature in the 
dark for different set lengths of time. Prior to challenge, serum and stool samples were collected. 
During the first 4 days post-challenge, serum samples were collected daily, as were all stool 
samples.  
The second study enrolled healthy secretor-positive adult volunteers, who were also 
challenged with Norwalk virus 8FIIb inoculum at Emory University Hospital’s Clinical 
Interaction Site between February 2008 and September 2009. They were randomized into control 
and intervention groups and administered oysters seeded with 1 x 10
4
 GEC of virus, which had 
been treated with high hydrostatic pressure processing for 5 minutes (intervention) or left 
untreated (control). Pre-challenge stool and serum samples were collected before challenge. 
During the first 4 days post-challenge, serum samples were collected daily, as were all stool 
samples.  
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The Emory University Institutional Review Board approved both studies, and both were 
registered on Clinical Trials.gov (identifiers NCT00313404 and NCT00674336). All subjects 
consented to the future use of all biological specimens from the studies. All specimens were 
stored at -80°C. 
Of the initial participants in both NoV challenge studies, a total of 26 became infected as 
defined by a NoV-positive stool or emesis sample tested by RT-PCR (limit of detection: 3,570 
GEC/g stool) [15, 17]. These 26 were pair-matched by age to 26 of the challenge study 
participants who remained uninfected following NoV challenge. Some infected subjects from 
one challenge group were matched with uninfected subjects from a different challenge group 
because within the same group there were no uninfected individuals within 3 years of age of the 
infected individual. The total sample size for this study was 52 participants (13 from the 2006 
trial, 39 from the 2008-2009 trial). Because the focus of this study is the acute immune response, 
only serum samples from pre-challenge and days 1-4 post-challenge were included, for a total of 
five longitudinal samples per subject. 
Inoculum 
 The two NoV challenge studies included participants who ingested water or shellfish 
seeded with 8FIIb NoV inoculum. The water samples were seeded with identical amounts of 
NoV and stored at room temperature in the dark for varying lengths of time. They showed no 
evidence of titer attenuation over time, as measured by RT-PCR [15]. Therefore, for these 
subjects, the regression models did not control for study arm. The shellfish samples were seeded 
with identical amounts of NoV and treated under varying processing conditions. The inocula 
showed some evidence of attenuation for some treatments.  For subjects from this study, all 
adjusted models controlled for study arm as a surrogate for dose. 
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Detection of viral shedding 
 NoV presence was measured by RT-PCR for all stool and emesis samples at all time 
points during the original challenge studies. A subject with a positive sample at any time point, 
even after day 4 post- exposure, as determined in the original or subsequent studies, was defined 
as infected.  
Detection of cytokines 
 Serum samples from pre-challenge (pre-challenge), and days 1-4 post-challenge (five 
total samples) were analyzed from all study subjects. Serum was collected during the studies, 
processed, and stored at -80°C until testing. Samples were tested by a commercial laboratory 
(EMD Millipore Corporation Discovery and Development Solutions) using a Milliplex human 
cytokine 16-plex assay for IFN-α2, IFN-γ, IL-1a, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12p40, IL-12p70, MCP-1, TNF-α, and TNF-β. Samples were run in duplicate with 
controls. Standard curves were generated using recombinant cytokines and calculated using a 
five parameter logistic model for each cytokine. Lower limits of detection (LLOD) were 3.2 
pg/mL for IFN-γ, IL-10, IL-12p70, IL-1b, IL-2, IL-5, IL-6, IL-8, MCP-1, and TNF-α; 16.0 
pg/mL for TNF-β; and 80.0 pg/mL for IFN-α2, IL-12p40, IL-1ra, IL-1a, and IL-4. Values below 
LLOD were assigned the value of the LLOD. 
Statistical analysis 
 The data were analyzed using SAS 9.4 (Cary, NC, USA). When possible, age and 
inoculum were controlled for in adjusted analyses. Because the exact amount of infectious NoV 
in the inocula for study arms with attenuation was unknown, inoculum was controlled for using a 
categorical variable for each study and study arm. The Wilcoxon signed rank test was to test for 
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the significance of the unadjusted difference between pre-challenge and post-challenge serum 
cytokine levels. Conditional logistic regression was used to evaluate the association between pre-
challenge and post-challenge fold changes in serum cytokine levels (i.e. ratio between post-
challenge and pre-challenge cytokine concentrations), controlling for inoculum and age. To 
summarize the differences between infected and uninfected individuals responses over time 
while accounting for correlation between time points, a mixed linear model was used to test the 
association between log10 cytokine concentration and day post-challenge, stratified by infection 
status with a random effect by subject, autoregressive correlation between different time points 
taken for the same individual, and fixed effect for inoculum. The parameter estimates for the 
effect of each day on log10 cytokine concentration for each stratum were averaged and Student’s 
t-test was used to compare infected and uninfected subjects cytokine responses over time. 
Conditional logistic regression adjusted for inoculum and age was also used to assess whether 
three measures of early cytokine levels or responses could be used as predictors of post-
challenge infection. The measures assessed were pre-challenge log10 cytokine concentration, pre-
challenge to day 1 post-challenge log10 cytokine change, and pre-challenge to day 1 post-
challenge fold change. All cytokines were modeled individually. Differences between groups 
were considered statistically significant at p < 0.05. 
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Results 
 To determine the acute serum cytokine response to GI.1 NoV infection, serum cytokine 
responses in individuals who became infected following experimental challenge were compared 
to those who remained uninfected after challenge, as determined by RT-PCR detection of GI.1 
NoV RNA in stool or emesis samples. Immune responses may differ with age, therefore the 
infected and uninfected subjects were matched for age (Table 1). The study population was 
relatively young, with a mean age of 26.7 years and a median age of 25 years. There was also a 
similar distribution of sex and race between infected and uninfected subjects selected for the 
study, though neither was a matching factor. Some uninfected subjects exhibited symptoms, 
including fever and diarrhea, which is consistent with past NoV challenge studies [16]. All 
infected individuals had higher cumulative shedding than the inoculum dose (data not shown), 
reducing the likelihood of misclassification of infection status because of detection of inoculum 
post-challenge in the absence of infection. Serum samples were available for pre-challenge 
through day 4 post-challenge (five time points) and all samples were tested for 16 serum 
cytokines. Two subjects did not have samples for day 3 and values for these samples were 
imputed using the average of neighboring observations for the same subject. A total of 10 
subjects had invalid test results for one or more cytokine tested (29 total observations). Using 
imputation, all but one of these invalid results was estimated to be below the LLOD.  
 Studies of serum cytokine levels in humans often have high rates of observations below 
the LLOD [18]. Overall of the 16 cytokines tested, nine had greater than 50% of observations 
above the LLOD, and four had greater than 75% of observations above the LLOD (Table 2). In 
general, infected subjects had more samples above the LLOD.  
 To assess whether serum cytokines exhibited a change in concentration following NoV 
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challenge, the Wilcoxon signed rank test was used, stratifying by infection status. Among 
infected individuals, there were significant increases in IL-2, IL-10, MCP-1, and TNF-α in the 
days post-challenge (Figure 1, all p < 0.05). Among uninfected individuals, there were no 
significant changes in serum cytokine concentrations post-challenge compared to pre-challenge. 
Based on conditional logistic regression models controlling for age and inoculum, there were no 
significant differences between infected and uninfected individuals’ changes in serum cytokine 
concentrations between pre-challenge and day 1 post-challenge (data not shown). However, 
infected individuals were significantly more likely to have increased IFN-γ, IL-6, IL-8, IL-
12p70, MCP-1, and TNF-α between pre-challenge and day 2 post-challenge compared to 
uninfected individuals (Table 3). Infected individuals were also significantly more likely to have 
increased levels of TNF-α, IL-8, and IL-10 from pre-challenge to day 3 post-challenge (all 
p<0.05; data not shown). At day 4 post-challenge, the only cytokine significantly elevated over 
pre-challenge levels was IL-10, which was significantly elevated in infected individuals (OR of 
infection based on a two-fold increase in IL-10 from pre-challenge to day 4 post-challenge=3.92, 
p=0.049; data not shown).  
Differences between infected and uninfected individuals over time 
Overall trends in serum cytokine response were analyzed using mixed models to account 
for correlation within subject over time (Figure 2). For infected individuals compared to 
uninfected individuals, there were statistically significant fold changes across the four days post-
challenge from pre-challenge levels in most serum cytokines measured (i.e. IFN-α2, IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10, MCP-1, TNF-α, and TNF-β, Figure 2), with all but TNF-β significantly 
higher in infected individuals compared to uninfected individuals. All cytokines peaked at day 2 
post-challenge among infected subjects, with the exception of IL-1ra, but many were elevated by 
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day 1 post-challenge (i.e. IL-2, IL-6, IL-8, MCP-1, and TNF-α) or remained elevated through 
day 4 post-challenge (i.e. IL-10) (Figure 2).  
Pre-challenge predictors of infection  
To determine if pre-challenge serum cytokine concentrations or early cytokine responses 
could predict infection status following challenge, the associations were estimated between 
infection status and three measures of serum cytokines: log10 serum cytokine concentration, log10 
difference between pre-challenge and day 1 post-challenge serum cytokine concentrations, and 
pre-challenge to day 1 post-challenge fold change (i.e. ratio between pre-challenge and day 1 
post-challenge concentrations). Across these measures, the only significant predictor of infection 
status was pre-challenge to day 1 post-challenge log10 change in MCP-1 concentration (data not 
shown). An increase of 1 log10 over this time period was associated with an OR of infection of 
5.74 (p=0.018). No other measures of early cytokine response were statistically significant 
predictors of infection. 
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Discussion 
 This study found overall significant elevation in IFN-a2, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, MCP-1, TNF-α, and TNF-β in infected subjects compared to uninfected subjects. Among 
infected individuals, these cytokines peaked on day 2 post-challenge. The results suggest that 
NoV infection elicits a Th1- and Th2-type response. There also was persistent elevation of IL-10 
among infected subjects, suggestive of an evolving early adaptive immune response and down-
regulation of Th1 cytokines. This study represents the first comprehensive description of the 
dynamics of serum cytokines in the acute time period following NoV challenge, including the 
largest number of cytokines simultaneously described for NoV infection (Table 3).  
 We found that before challenge, individuals who became infected following NoV 
challenge were similar to individuals who did not become infected with regard to all 16 
cytokines tested. From these similar pre-challenge features, differences began to emerge as early 
as 24 hours post-challenge and persisted through day 4 post-challenge. As previously 
documented with human Snow Mountain strain (SMV; GII.2) infection, there was a significant 
Th1 response (i.e. IFN-γ, IL-2, and TNF-α) with significant elevation of one Th2-related 
cytokine (Table 3) [13]. In this study, some Th2 and other cytokines (e.g. IL-4, IL-5, IL-6, IL-8, 
and IL-10) were also significantly elevated following NoV challenge in infected individuals.  
The cytokine responses also resembled results from animal studies (Table 3) but differed 
in the timing and magnitude of cytokine response [19, 20]. These results suggest that the immune 
response by gnotobiotic animals to human NoV may be substantially different from the response 
in humans, perhaps due to the gnotobiotic animals’ immature immune systems [21] or because of 
the use of a different NoV inoculum. 
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Initial response: IL-8, MCP-1 
 We found that IL-8 levels increased in infected subjects by day 1 post-challenge and 
remained elevated through day 3 post-challenge. IL-8 elevation has been identified in prior field 
studies of NoV infection (Table 3) [22, 23]. IL-8 is a powerful chemoattractant for neutrophils 
[24, 25] and intraepithelial lymphocytes [26, 27], and a key mediator of the immune response to 
other gastrointestinal pathogens [28]. Histologic findings from previous human NoV challenge 
studies show increases in granulocyte and monocyte cells in the lamina propria of the small 
intestine 12-48 hours after challenge in infected subjects [29]. Based on the rise in IL-8 alongside 
an increase in MCP-1 and a later rise in IL-6, two monocyte chemoattractants, these observations 
are consistent with neutrophil recruitment acting in concert with monocyte response to NoV 
infection. Earlier work found that GI and GII NoV infection is associated with elevated fecal 
MCP-1, suggesting local monocyte activation [23], but this study is the first to show elevated 
serum MCP-1, suggesting a systemic response as well.   
TNF-α and symptoms 
 In this study, the peak serum TNF-α concentration at 48 hours post-challenge 
corresponded with the time most NoV-infected individuals were symptomatic. TNF-α increases 
cellular permeability, leading to edema mucosal damage [30]. Elevated TNF-α has also been 
associated with NoV infection in past human and animal studies (Table 3) [19, 23]. In some 
gastrointestinal infections, TNF-α is associated with symptoms [31-33]. The association between 
TNF-α and NoV symptoms is an important area for future research. 
IL-6  
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 IL-6 is a multi-functional cytokine with strong pro-inflammatory effects. It is associated 
with damage to the intestinal mucosa [29] and increased frequency of diarrhea [22], suggesting a 
role in pathogenesis and clinical severity of illness. In this study, IL-6 was significantly elevated 
on day 2 post-challenge. This confirms some clinical studies’ identification of the association 
between IL-6 and NoV infection but contrasts with the results from a SMV challenge study 
(Table 3) [13, 22, 23] and suggests possible strain-related differences in immune response. This 
study reported a median maximum serum IL-6 level that was higher than prior studies have 
identified [22, 34], but this discrepancy may be the result of differences in sample collection.  
IL-10 persistently elevated 
 Though IL-10 peaked on day 2 post-challenge, it was significantly elevated through day 4 
post-challenge. This suggests an ongoing role in NoV infection beyond the acute time period. IL-
10 is involved in the Th2 response and B-cell development [35], so its elevation may be 
associated with the development of NoV-specific antibodies, which begin to be detectable 
around or before day 7 post-challenge [36, 37]. Elevated IL-10 in the context of NoV infection 
has been described in prior studies of human NoV (Table 3). IL-10 may also play an anti-
inflammatory role in down-regulating Th1 cytokine production. The significant elevation of IL-
10 in infected subjects following the elevation of Th1 cytokines supports the conclusion that 
NoV elicits a Th1-type response. Furthermore, IL-10-deficient mice exhibit mucosal 
inflammation and epithelial barrier dysfunction following MNV-challenge, whereas wildtype 
mice do not [38]. It is possible that IL-10 plays a similar protective role in NoV-challenged 
humans.  
Strengths and Limitations 
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 This study used rigorously collected human NoV challenge study data, which provided a 
detailed, longitudinal dataset. It is the largest collection of human NoV challenge subjects yet 
studied for serum cytokine response. It represents broadest panel of cytokines yet examined at 
one time for human NoV infection. Some limitations of this study are that it may have been 
underpowered to detect some changes in serum cytokines, the exposure history of subjects prior 
to NoV challenge was unknown, and there is the possibility that the duration of sample storage 
may have caused cytokine degradation [39]. An additional limitation of the study is that though 
RT-PCR is the gold-standard for NoV testing, there may have been individuals who were 
misclassified as uninfected because they shed virus at levels below the limit of detection. 
Conclusion 
 Although NoV remains a major cause of morbidity worldwide, some aspects of the 
immune response continue to be poorly understood. To develop effective vaccines and 
prophylaxis, it is important to understand the human acute immune response to NoV. This study 
demonstrated a Th1- and Th2-type response to GI.1 NoV infection, early elevation of 
chemokines IL-8 and MCP-1, and ongoing elevation of IL-10. This work confirms earlier 
findings of the increase in MCP-1 associated with NoV infection, suggesting macrophage and 
dendritic cell involvement in NoV infection. These findings buttress the existing findings from 
MNV models and enhance the depth of knowledge regarding the human cytokine response to 
NoV. Differences between the results of this study and those of other human and animal work 
may be attributable to strain-related variability in immune response. Future work should consider 
the interplay between the immune response and both clinical outcomes and viral shedding to 
understand NoV pathogenesis and help develop clinical and public health strategies to reduce 
NoV transmission.
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Figure Legends 
 
Figure 1: Comparison of pre-challenge to post-challenge serum cytokine concentrations in 
norovirus-challenged individuals, stratified by infection status (infected n=26, uninfected n=26).  
Values below the lower limit of detection (LLOD) were assigned to the value of the LLOD. 
Significance of change from pre-challenge value was tested using Wilcoxon test and is denoted 
by an asterisk above the relevant category. Interquartile ranges (IQRs) for infected individuals 
(gray boxes) and for uninfected individuals (white boxes) are shown. Dark lines indicate median 
values. Whiskers indicate most extreme value that is no more than 1.5 times the IQR away from 
the bound of the IQR. Circles indicate outliers. *p<0.05, **p<0.01, ***p<0.001 
Figure 2. Mixed linear model results for the association between log10 cytokine change from pre-
challenge to post-challenge by day, with fixed effects for inoculum dose and day and a random 
effect by individual subject. Solid line: infected individuals, dashed line: uninfected individuals. 
Points represent estimates of the effect of day on change in cytokine concentration. Error bars 
indicate one standard error. P-value indicates significance of overall elevation in cytokine 
concentration across days.  
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Table 1: Characteristics of norovirus-challenged individuals included in analytic sample 
 
 
Total (n=52) Infected (n=26) Uninfected (n=26) 
Age (mean, SD) 26.7 (7.6) 26.7 (7.5) 26.7 (7.9) 
Female  32 (61.5%) 17 (65.4%) 15 (57.7%) 
Race    
     White 25 (48.1%) 15 (57.7%) 10 (38.5%) 
     Black 21 (40.4%) 8 (30.8%) 13 (50.0%) 
     Other 6 (11.5%) 3 (11.5%) 3 (11.5%) 
AGE symptoms
a
  19 (33.9%) 17 (65.4%) 2 (7.7%) 
Modified Vesikari score (mean, SD) 2.6 (2.4) 4.1 (2.4) 1.1 (0.9) 
Abbreviations: SD, standard deviation; AGE, acute gastroenteritis. 
a
AGE symptoms defined as diarrhea (3 or more or >= 400g loose stools in 24 hours) or emesis during days 1-4 post-
challenge.  
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Table 2. Serum cytokine concentrations (pg/mL) of norovirus-challenged individuals pooled 
across days, stratified by infection status
a
. 
All 
 
Infected 
 
Uninfected 
Cytokine Median IQR 
% 
above 
LLOD 
 
Median IQR 
% 
above 
LLOD 
 
Median IQR 
% 
above 
LLOD 
IFN-α2 80.0 80.0-80.0 24.8%  80.0 80.0-133.0 27.9%  80.0 80.0-80.0 21.7% 
IFN-γ 186.5 40.4-
656.1 
90.3%  182.0 67.9-629.3 98.4%  188.3 18.2-669.5 82.2% 
IL-1ra 80.0 80.0-
999.3 
54.3%  80.0 80.0-389.1 73.6%  80.0 80.0-
1,993.9 
34.9% 
IL-1a 163.4 80.0-
433.2 
24.7%  179.8 80.0-433.2 28.5%  80.2 80.0-
433.55 
21.1% 
IL-1b 3.2 3.2-10.3 58.9%  3.3 3.2-18.45 70.2%  3.2 3.2-7.2 48.1% 
IL-2 4.6 3.2-30.1 47.8%  7.5 3.2-38.2 48.0%  3.6 3.2-17.6 47.6% 
IL-4 80.0 80.0-99.9 54.7%  80.0 80.0-170.9 59.4%  80.0 80.0-80.0 50.0% 
IL-5 3.2 3.2-3.9 38.4%  3.2 3.2-6.0 48.1%  3.2 3.2-3.2 28.7% 
IL-6 23.9 3.2-120.2 52.5%  27.8 3.2-93.0 55.5%  21.4 3.2-161.1 49.6% 
IL-8 66.5 20.7-
198.1 
25.4%  81.7 34.2-198.0 28.9%  45.0 11.5-202.4 21.9% 
IL-10 4.4 3.2-29.5 26.8%  17.0 3.2-50.3 33.9%  3.2 3.2-6.2 19.7% 
IL-12p40 80.0 80.0-80.0 70.7%  80.0 80.0-85.0 69.5%  80.0 80.0-80.0 71.9% 
IL-12p70 6.1 3.2-89.8 92.2%  19.5 3.2-86.6 96.9%  3.2 3.2-96.0 87.6% 
MCP-1 612.8 397.1-
832.5 
100.0%  693.5 510.8-
944.3 
100.0%  495.1 329.4-
673.1 
100.0% 
TNF-α 14.3 6.0-27.2 85.3%  15.1 8.3-25.2 87.6%  14.0 4.9-36.2 82.9% 
TNF-β 16.0 16.0-58.5 37.2%  16.0 16.0-100.5 35.7%  16.0 16.0-33.4 38.8% 
Abbreviations: IQR, inter-quartile range; LLOD, lower limit of detection; IFN, interferon; IL, interleukin; MCP, 
monocyte chemoattractant protein; TNF, tumor necrosis factor. 
a
Values below LLOD included in estimates as LLOD value. 
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Table 3. Table comparing results from this study to prior studies of cytokine responses to human 
NoV infection. An ‘x’ indicates significant elevation compared to uninfected controls. Gray cells 
indicate no testing was conducted for that cytokine.  
Study This study
a Lindesmith 
2005 [12] 
Long 2011 [22] 
Chen 2012 
[37] 
Souza 2008 
[18] 
Souza 
2007 [19] 
NoV genogroup GI.1 GII.2 Mixed Mixed GII.4 GII.4 
Subjects Human Human Human Human Gn Calf Gn Pig 
Study design Challenge Challenge 
Observational 
cohort 
Cross-
sectional 
Challenge Challenge 
Cytokine 
IFN-α x 
IFN-α2 ns 
IFN-γ x x ns x
b 
x 
IL-1ra ns 
IL-1a ns 
IL-1b ns 
IL-2 x x 
IL-4 ns ns ns x
b
 x 
IL-5 ns x x 
IL-6 x ns x x 
IL-8 x x x 
IL-10 x ns ns x
b
 x 
IL-12 x
b
 x 
IL-12p40 ns 
IL-12p70 x 
MCP-1 x x 
TNF-α x ns ns x
b
 
TNF-β ns 
Abbreviations: ns, not significant; NoV, norovirus; Gn, gnotobiotic. 
a
Modeled using conditional logistic regression conditional on inoculum dose and adjusted for age. 
b
Cytokine 
concentrations were elevated compared to controls but no statistical testing was conducted. 
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